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S380 Poster Session IILimitations to the study include a small sample size and an arbitrarily
determined threshold to administer P. A cost-based analysis is cur-
rently being performed to help determine the best day 4 CD34 cutoff
for future studies.
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POTENTIAL COST BENEFIT OF PEGFILGRASTIM COMPARED TO DAILY
FILGRASTIM FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION
AT A LARGE TEACHING HOSPITAL
Weber, C.1, Earl, M.1, Kalaycio, M.2 1Cleveland Clinic, Cleveland, OH;
2Cleveland Clinic, Cleveland, OH
The ability of filgrastim (G-CSF) to potentiate hematopoietic recov-
ery following autologous hematopoietic cell transplantation (HCT) is
well-documentedand is currently the standardof care.1 Its use following
allogeneic HCT is less well-delineated, but is often practiced clinically.
Pegfilgrastim, given once every 14 days, is a convenient and potentially
economic alternative to daily G-CSF administration. We retrospec-
tively evaluated the utilization of G-CSF following HCT and its asso-
ciated cost acquisition among 605 total patients transplanted at
a large teaching hospital. Between 1/1/2007 and 8/17/2011, 165 pa-
tients received an allogeneic HCT and an average of 17 doses of G-
CSF (range 2-131) following transplant. Of these patients, 26 received
umbilical cord blood, 113 received bone marrow, and 26 patients re-
ceived peripherally mobilized cells. During the same time period, 440
peripherally mobilized autologous HCT patients received an average
of six daily G-CSF doses (range 1-33). The average wholesale price
(AWP) of G-CSF 480 mcg and pegfilgrastim 6 mg is $477.18 and
$4218.00, respectively. Therefore, pegfilgrastim offers institutional
cost savings if greater than 8 doses of G-CSF are administered. At our
institution during the year 2010, 41 allogeneicHCTand 99 autologous
in-patientHCTwere performed. Substitution ofG-CSFwith one dose
of pegfilgrastim, followed by dailyG-CSFdosing as clinically appropri-
ate, would have decreased our yearly cost expenditures for allogeneic
HCT by approximately $101,000. However, yearly cost expenditures
for autologous HCT would have increased by $179,000. Given that
the use of pegfilgrastim appears to be both safe and efficacious when
compared to daily G-CSF following HCT,2-5 it is reasonable to con-
sider use of this agent, particularly among allogeneic HCT recipients
due to the economic benefit and convenience in administration.
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PBSC MOBILIZATION FOR AUTOLOGOUS TRANSPLANTATION IN MULTI-
PLE MYELOMA AFTER INTENSIVE CHEMOTHERAPY IN PATIENTS WITH
SEVERE RENAL DYSFUNCTION RECEIVING HEMODIALYSIS RESCUE
POST CYCLOPHOSPHAMIDE
Rogosheske, J.R.1, MCClune, B.L.2 1University of Minnesota Medical
Center, Fairview, Minneapolis, MN; 2University of Minnesota, Minne-
apolis, MN
Peripheral blood stem cell (PBSC) mobilization with high dose
(HD) cyclophosphamide (CY) 4gm/m2 and rh-GCSF (10 mg/kg/d)
is routinely used to produce sufficient numbers of stem cells into
the peripheral blood for collection with the added benefit of reduc-
ing tumor load. Guidelines for dosing CY in patients with severe re-
nal dysfunction recommend a dose reduction but could affect
mobilization, disease progression and length of survival. We de-
scribe the outcome of rescue hemodialysis post HD CY on PBSC
collections and CY-related toxicities. Three patients with multiple
myeloma and severe renal insufficiency were given HD CY then un-
derwent 6- hour high flux hemodialysis beginning 14 hours after the
end of the CY infusion. The hemodialysis was timed to remove any
accumulation of CY and its metabolites to prevent unnecessary tox-
icity but also to allow sufficient efficacy and mobilization of stem
cells to occur. The control group (n5 10) had normal renal function
(GFR\70ml/min) and was matched to disease, gender and age. The
mean time to complete stem cell collections (target dose 5 x10^6
CD34 cells/kg) was 24 days (20-26) compared to a control group
of 14 days (10-29). After mobilization the median cell yield was 3.9
x 10^6 CD34 compared to 8.37 x 10^6 CD34 in the control group.
No severe CY toxicities were observed.We conclude that single HD
CY priming in patients with severe renal dysfunction rescued by he-
modialysis effectively produces PBSC but the time to collections
may be delayed and the yield reduced.480
LEVETIRACETAM IS EFFICACIOUS FOR PREVENTION OF BUSULFAN IN-
DUCED SEIZURES
Frame, D.1,Martell, A.1,Markstrom,D.1, Choi, S.2, Couriel,D.2 1Univer-
sity of Michigan, Ann Arbor, MI; 2University of Michigan, Ann Arbor, MI
High-dose busulfan is used in several conditioning regimens in pa-
tientsundergoingallogeneichematopoietic cell transplant (HCT).Bu-
sulfan is known to reduce the seizure threshold, and historically, has
contributed to partial or generalized seizures in up to 10% of patients
without a known history of seizures. Phenytoin has been the primary
agent used in preventing busulfan-induced seizures inmany transplant
programs. However, due to concerns of drug interactions, side effects,
and dosing issues, phenytoin is not an ideal agent in the HCT setting.
For these reasons, the primary prophylaxis at the University of Mich-
igan was changed in April 2009 from phenytoin to levetiracetam 1000
mg twice daily beginning 12 hours prior to Busulfan through 48 hours
after the last busulfan dose for adults and 10mg/kg/dose twice daily
(max1000mg) for children.This retrospective reviewcompared levetir-
acetam (N5 125) to phenytoin (N5 220) for busulfan seizure prophy-
laxis at this single-institution (January 2007- February 2011). Standard
dosing for phenytoin in adult patients was 1000 mg total dose in 3 di-
vided doses beginning the day prior to the initiation of Busulfan, fol-
lowed by 2.5 mg/kg/dose PO twice daily, and continuing for 24 hours
after the last dose of Busulfan; and in children, 5- 7.5mg/kg/dose given
in 3 doses the evening prior to the initiation of Busulfan, followed by
a maintenance dose of 2.5 mg/kg/dose twice daily to be given 24 hours
after the last dose of Busulfan. A free phenytoin level was obtained prior
to the initiation of Busulfan with subsequent daily levels until a thera-
peutic goal level of 1-2 was achieved. Busulfan-based conditioning reg-
imens included: BuCy2, BuCy4, CloBu4, FluBu2, and FluBu4,
respectively. There were two seizures in patients who received phenyt-
oin compared to none in those who received levetiracetam. Based on
thesefindings combinedwith a significant decrease indrug interactions,
levetiracetam is the primary agent for busulfan seizure prophylaxis.
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IMPROVING VACCINATION OF PATIENTS PRE AND POST BONE MARROW
TRANSPLANT
Cooper, J., Krugh, D., Duda, J., Roddy, J., Klisovic, R., Lamprecht, M.,
Beavers-Kirby, J., Hofmeister, C., Dishon-Ritzert, J., Devine, S.OSUCCC
James Cancer Hospital and Solove Research Institute, Columbus, OH
TheOhio State University James Cancer Hospital and Solove Re-
search Institute Blood and Marrow Transplant (BMT) Program de-
veloped a vaccination program (VP) for BMT patients. Several
obstacles were identified that prevented a VP. These included cost,
absence of standard plan of care (POC), and staff awareness of vacci-
nation schedule. An initial POCwas developed in 2008 based on his-
torical data. Twenty-four months after implementation, a quality
assessment (QA) revealed that only 7.6% of allogeneic BMTpatients
had appropriate vaccinations documented at 12 months status post
transplant. A best practice order set was introduced to the outpatient
clinicians who regularly evaluate these patients. Six months after the
best practice order set was introduced, a random sample of 10 patient
charts revealed 100% compliance of the VP.
TheQA captured a snapshot of VP compliance of annual influenza
vaccination and vaccination for allogeneic BMT patients, beginning
12 months status post allogeneic transplant (Tdap, Hib, Hep B,
Pneumococcal, and IPV). For allogeneic BMT patients, only 10%
of the patients were not on immunosuppressive therapy (GvHD
grade 0-2). The QA revealed that allogeneic BMT patients received
annual influenza vaccination; however due to being on immunosup-
pressive therapy (IT) and based on current VP POC, did not receive
recommended vaccination at 12 months.
After a literature review, the revised VP POC was divided into pre-
and post BMT, with distinctions for autologous and allogeneic. Guide-
linesweredeveloped forBMTpatientswith thrombocytopenia, apoten-
tial lapse in the vaccination schedule, patient’s family members, related
BMT donors, and BMT Program staff who may have received live-at-
tenuated vaccination (varicella) during employee health evaluation.
Despite an existing plan of care, there were numerous quality im-
provement opportunities. Evidence based practice should continu-
ously be reviewed and implemented into practice with annual
review of policies, procedure and/or plans of care.
